Skip to main content

30-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Final analysis of KEYNOTE-189

Delvys Rodriguez-Abreu reports the final analysis of the KEYNOTE-189 trial of pembrolizumab plus chemotherapy for patients with nonsquamous non-small-cell lung cancer (4:51).

Enriched treatment pathway for non-driver NSCLC

What is it and why do I need it?

Have your say on Medicine Matters

Visit the conference hub

Image Credits